

Code Updates

September 2024

Drug Code Updates

The following drug(s) are now covered under the medical benefit with prior authorization for Commercial/ASO Plans:

| Code | Description | Brand Name | Effective Date |
|------------------------|---|-------------------------------------|-------------------|
| No Specific Code | Liquid, (human-stwk) immune globulin intravenous, 10% | Alyglo | 8/1/2024 |
| J7355 | Injection, travoprost, intracameral implant, 1 mcg | iDose TR intracameral implant | 8/1/2024 |
| No Specific Code | Injection, spesolimab-sbzo, for subcutaneous use | Spevigo SC | 8/1/2024 |

The following drug(s) are now covered under the medical benefit without prior authorization for Commercial/ASO Plans:

| Code | Description | Brand Name | Effective Date |
|-------|---|-------------|-------------------|
| J9172 | Injection, docetaxel (Ingenus), not therapeutically equivalent to J9171, 1 mg | Docivyx IV | 8/1/2024 |
| J1434 | Injection, fosaprepitant (Focinvez), 1 mg | Focinvez IV | 8/1/2024 |

The following drug(s) are not covered under the medical benefit for MGB ACO Plans; Submit to Pharmacy Benefit:

| Code | Description | Brand Name | Effective Date |
|----------|--|------------|-------------------|
| No | Injection, spesolimab-sbzo, for subcutaneous use | Spevigo SC | 8/12/2024 |
| Specific | | | |
| Code | | | |

The following drug(s) are now covered under the medical benefit with prior authorization for MGB ACO Plans:

| Code | Description | Brand Name | Effective |
|------|-------------|------------|-----------|
| | | | Date |
| | | | |

| No | Liquid, (human-stwk) immune globulin intravenous, 10% | Alyglo | 10/1/2024 |
|----------|---|-------------|------------|
| Specific | | | |
| Code | | | |
| J1434 | Injection, fosaprepitant (Focinvez), 1 mg | Focinvez IV | 11/12/2024 |

The following drug(s) are now covered under the medical benefit without prior authorization for MGB ACO Plans:

| Code | Description | Brand Name | Effective Date |
|-------|---|------------|-------------------|
| J9172 | Injection, docetaxel (Ingenus), not therapeutically equivalent to J9171, 1 mg | Docivyx IV | 8/1/2024 |

The following drug(s) are now covered under the medical benefit with prior authorization for Medicare Advantage Plans:

| Code | Description | Brand Name | Effective Date |
|------------------------|---|--------------|-------------------|
| Q5133 | Injection, tocilizumab-bavi (Tofidence), biosimilar, 1 mg | Tofidence IV | 8/1/2024 |
| No Specific Code | Injection, tocilizumab-aazg, IV | Tyenne IV | 8/1/2024 |

The following drug(s) are now covered under the medical benefit without prior authorization for Medicare Advantage Plans:

| Code | Description | Brand Name | Effective Date |
|-------|---|-------------------------------------|-------------------|
| J9172 | Injection, docetaxel (Ingenus), not therapeutically equivalent to J9171, 1 mg | Docivyx IV | 8/1/2024 |
| J1434 | Injection, fosaprepitant (Focinvez), 1 mg | Focinvez IV | 8/1/2024 |
| J7355 | Injection, travoprost, intracameral implant, 1 mcg | iDose TR intracameral implant | 8/1/2024 |

